DBV Technologies S.A. - ADR Peer Comparison

$12.37

$-0.14 (-1.12%)

As on 18-Sep-2026 16:00EDT

Market cap

$776 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.9

Div. Yield

0 %

Edit

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Market cap ($ Mln)	776	2,885	2,376	1,965	758
Revenue ($ Mln)	--	450	549	121	1
Net Profit ($ Mln)	-175.85	-188.21	17.88	-57.76	-59.95
Net Margin (%)	--	-41.86	3.26	-47.60	-9,759.23
RoE (%)	-106.84	-28.46	1.43	-9.91	-118.98
Price to Earnings	--	--	136.70	--	--
Price-To-Book	4.90	4.75	1.91	3.40	20.57

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Operating Revenue	0.00	449.61	549.12	120.79	0.61
Cost of Revenue	12.78	195.71	548.01	19.21	0.30
Gross Profit	-17.67	269.08	212.72	12.07	0.34
Operating Expenses	176.86	517.90	35.89	154.86	67.15
Operating Profit (EBIT)	-181.14	-264.00	-34.78	-118.11	-66.84
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-178.93	-190.72	20.08	-57.14	-59.95
Provision for Tax	-3.09	-2.51	1.66	0.62	0.00
Profit after Tax (Net Income)	-175.85	-188.21	17.88	-57.50	-59.95
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	0.00	0.00	0.00	0.00

Liabilities ($ Mln)

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Shareholder's Funds	160.40	607.04	1,260.78	568.41	38.47
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	8.50	39.17	186.25	123.56	55.23
Current Liabilities	54.30	428.58	275.21	81.11	12.71
Total Liabilities	233.72	1,172.38	1,753.10	784.68	131.44

Assets ($ Mln)

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Non-Current Assets	21.30	160.76	183.02	575.59	12.13
Current Assets	201.90	914.04	1,553.41	197.49	94.28
Total Assets	233.72	1,172.38	1,753.10	784.68	131.44
Total Debt*	21.00	254.58	94.51	127.33	0.11
Net Current Assets	147.60	485.45	0.00	116.38	81.57

Cashflow ($ Mln)

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Cash From Operating Activities	-121.18	-150.79	-64.66	-49.95	-62.27
Cash Flow from Investing Activities	-1.37	307.87	-29.41	0.12	-47.99
Cash from Financing Activities	276.18	72.35	7.84	147.34	0.02
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
ROCE (%)	-130.25	-18.15	41.92	-15.42	-104.49
ROE (%)	-106.84	-28.46	1.43	-10.06	-118.98
ROA (%)	-74.77	-12.55	0.66	-6.60	-40.08
EBIT Margin (%)	--	-41.09	-6.33	-42.43	-9,892.63
Net Margin (%)	--	-41.86	3.26	-47.60	-9,759.23
Cash Profit Margin (%)	--	0.00	--	--	-0.02

Growth Ratios

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Revenue Growth (%)	-1.00	5.10	-8.81	602.33	-97.63
EBIT Growth (%)	-45.21	11.36	-76.55	17.93	26.29
Net Profit Growth (%)	-43.04	11.44	-96.17	43.71	31.30
EPS Growth (%)	7.30	-1.87	-96.17	47.43	31.24
Book Value Growth (%)	108.85	-25.05	2.54	-6.65	-59.14

Valuation Ratios

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Price / Earnings	-9.99	-11.11	5.08	-13.58	-1.08
Price / Book Value	4.90	4.75	1.91	3.40	20.57
Dividend Yield (%)	0.00	0.00	0.00	0.00	0.00
EV/EBITDA	-3.50	-14.34	-53.94	-45.43	-11.17
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Debt to Equity	0.00	0.00	0.00	0.19	0.00
Short term debt to equity ratio	0.09	0.40	0.02	0.02	0.00
Current Ratio	3.72	2.13	5.64	2.43	7.42
Quick Ratio	3.72	1.92	5.50	2.09	7.42
Interest Coverage	--	-30.87	-19.05	-4.06	--

Operating Efficiency Ratios

	DBV Technologies S.A. - ADR	Zai Lab - ADR	HUTCHMED (China) - ADR	Mesoblast - ADR	Silence Therapeutics PLC (SLN)
Debtors to sales (%)	--	16.23	21.41	47.25	1,512.64
Asset Turnover	0.00	0.30	0.20	0.14	0.00
Receivable days	--	77.60	104.79	380.35	8,295.02
Inventory Days	--	109.55	49.57	791.94	--
Payable days	650.68	231.78	47.68	931.00	6,253.37
Cash Conversion Cycle	--	-44.63	106.67	241.30	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly